Ganciclovir ophthalmic gel 0.15: In acute herpetic keratitis (dendritic ulcers)

Drugs

Volumn 71, Issue 5, 2011, Pages 603-610

  Croxtall, Jamie D ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Ganciclovir; Keratitis; Ophthalmic

Indexed keywords

ACICLOVIR; GANCICLOVIR; VIRUS DNA;

ANTIVIRAL ACTIVITY; ARTICLE; BLURRED VISION; CONJUNCTIVAL HYPEREMIA; CORNEA ULCER; DRUG EFFICACY; DRUG TOLERABILITY; EYE IRRITATION; GEL; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; PUNCTATE KERATITIS; VIRUS INHIBITION;

ACUTE DISEASE; ADMINISTRATION, TOPICAL; ANIMALS; ANTIVIRAL AGENTS; GANCICLOVIR; GELS; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; KERATITIS, DENDRITIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 79953180067     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11207240-000000000-00000     Document Type: Article

References (27)

1. Liesegang TJ. Herpes simplex virus epidemiology and ocular importance. Cornea 2001 Jan; 20 (1): 1-13. (Pubitemid 32038147)
2. Chaney SM, Warren KG, Kettyls J, et al. A comparative analysis of restriction enzyme digests of the DNA of herpes simplex virus isolated from genital and facial lesions. J Gen Virol 1983 Feb; 64 (Pt 2): 357-71. (Pubitemid 13115960)
3. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006 Aug 23; 296 (8): 964-73. (Pubitemid 44285373)
4. Wilhelmus KR. The treatment of herpes simplex virus epithelial keratitis. Trans Am Ophthalmol Soc 2000; 98: 505-32. (Pubitemid 32063159)
5. National Eye Institute. Facts about the cornea and corneal disease [online]. Available from URL: http://www.nei.nih. gov/health/cornealdisease/ [Accessed 2010 Dec 21].
6. Foster C. Ganciclovir gel: a new topical treatment for her- petic keratitis. US Ophthal Rev 2008; 3: 52-6.
7. Kaye S, Choudhary A. Herpes simplex keratitis. Prog Retin Eye Res 2006 Jul; 25 (4): 355-80. (Pubitemid 44041113)
8. Tabbara KF. Pharmacologic strategies in the prevention and treatment of corneal transplant rejection. Int Oph-thalmol 2008 Jun; 28 (3): 223-32. (Pubitemid 351627108)
9. Wilhelmus K. Antiviral treatment and other therapeutic in- terventions for herpes simplex virus epithelial keratitis. Cochrane Database Syst Rev 2010; (12): CD002898.
10. O'Brien JJ, Campoli-Richards DM. Acyclovir: an updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1989 Mar; 37 (3): 233-309. (Pubitemid 19083613)
11. Kaufman HE. Ganciclovir: a promising topical antiviral gel for herpetic keratitis. Expert Rev Ophthalmol 2009; 4 (4): 367-75.
12. McGavin JK, Goa KL. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 2001; 61 (8): 1153-83. (Pubitemid 32661232)
13. Faulds D, Heel RC. Ganciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 1990 Apr; 39 (4): 597-638.
14. Crumpacker CS. Ganciclovir. N Engl J Med 1996 Sep 5; 335 (10): 721-9.
15. Trousdale MD, Goldschmidt PL, Nobrega R. Activity of ganciclovir against human adenovirus type-5 infection in cell culture and cotton rat eyes. Cornea 1994 Sep; 13 (5): 435-9. (Pubitemid 24260318)
16. Drug Information Online. Virgan eye gel [online]. Available from URL: http://www.drugs.com/uk/virgan-eye-gel-spc-3322.html [Accessed 2011 Mar 2].
17. Bausch & Lomb Inc. Zirgan (ganciclovir ophthalmic gel 0.15%): US prescribing information [online]. Available from URL http://www.bausch.com/en- US/downloads/ecp/pharma/Zirganpackage-insert.pdf [Accessed 2011 Mar 2].
18. Matthews T, Boehme R. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis 1988 Jul 31; 10 Suppl 3: S490-4.
19. Colin J. Ganciclovir ophthalmic gel, 0.15%: a valuable tool for treating ocular herpes. Clin Ophthalmol 2007 Dec; 1 (4): 441-53.
20. Levin MJ, Bacon TH, Leary JJ. Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. Clin Infect Dis 2004 Nov 1; 39 Suppl 5: S248-57. (Pubitemid 39447300)
21. Duan R, de Vries RD, Osterhaus AD, et al. Acyclovir- resistant corneal HSV-1 isolates from patients with her-petic keratitis. J Infect Dis 2008 Sep 1; 198 (5): 659-63.
22. Hoh HB, Hurley C, Claoue C, et al. Randomised trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: a multicentre study. Br J Ophthalmol 1996 Feb; 80 (2): 140-3. (Pubitemid 26058547)
23. Chribret H, Elena PP, Khosravi E. Ocular pharmacokinetics of topically-applied ganciclovir in rabbits with intact or removed corneal epithelium [abstract no. 1712]. Invest Ophthalmol Vis Sci 1993; 34 (4): 1050.
24. Elena PP, Goldschimdt P, Chast F, et al. Distribution of ganciclovir in the anterior uvea after topical application of 0.15% ganciclovir gel to the intact HSV-infected eyes of rabbits [abstract no. 1984]. Invest Ophthalmol Vis Sci 1994; 35 (4): 1682.
25. Khosravi E, Elena PP, Goldschimdt P, et al. Ocular bioavailability of ganciclovir gel, an anti-herpetic formulation, after topical administration to intact or removed corneal epithelium of rabbit eyes [abstract no. 383]. Invest Ophthalmol Vis Sci 1996; 37 (3): S81. (Pubitemid 126821863)
26. Colin J, Hoh HB, Easty DL, et al. Ganciclovir ophthalmic gel (Virgan; 0.15%) in the treatment of herpes simplex keratitis. Cornea 1997 Jul; 16 (4): 393-9. (Pubitemid 27282176)
27. US FDA. NDA 22-211 Medical review(s): ganciclovir ophthalmic gel 0.15% [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 2009/022211s 000-MedR.pdf [Accessed 2011 Jan 17]